ArticleDiagnostic pathology2026
Diffuse co-expression of TTF-1 and p40 (ΔNp63) defines a distinct biphenotypic non-small cell lung carcinoma: clinicopathologic and molecular characterization of 19 cases.
Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe diffuse co-expression of thyroid transcription factor-1 (TTF-1) and p40 defines a rare and diagnostically challenging subtype of non-small cell lung carcinoma (NSCLC). Due to its extreme rarity, the clinicopathologic and molecular characteristics of this entity remain poorly characterized.
methodsWe conducted a comprehensive analysis of the largest single-institution cohort to date (n = 19) of NSCLCs with diffuse TTF-1/p40 co-expression. All cases underwent detailed histopathologic review. Immunohistochemistry (IHC) utilized specific antibody clones (TTF-1: 8G7G3/1; p40). Molecular profiling was performed via next-generation sequencing in a subset of cases, including multi-region analysis for select tumors.
resultsThe cohort mainly consisted of elderly male smokers (median age 65; 84.2% male; 73.7% smokers). Anatomically, 84.2% of tumors were located in the right lung, mainly in the upper lobe, with no clear preference for central or peripheral distribution. Histologically, all were poorly differentiated NSCLCs, classifiable into two patterns: a basaloid/squamous-like pattern and an inflammatory/plasmacytoid pattern. Molecular profiling revealed a hybrid genomic landscape, with individual tumors harboring alterations linked to both adenocarcinoma and squamous cell carcinoma, along with a high prevalence(58.8%) of TP53 mutations. In an index case, multi-region sequencing revealed a shared EGFR mutation across regions, with a TP53 mutation confined to the high-grade TTF-1/p40-positive area. Most patients (66.7%) presented with Stage III or IV disease, and 61.1% developed metastases, including four with distant spread and seven involving thoracic or supraclavicular lymph nodes or the pleura. Three patients died from the disease within 10–64 months after diagnosis. However, all patients with Stage I or II disease who underwent resection remained disease-free.
conclusionsNSCLC with diffuse TTF-1/p40 co-expression constitutes a distinct biphenotypic entity with unique clinicopathologic and molecular features. We suggest specific diagnostic criteria to ensure proper identification. Given the presence of targetable drivers and frequent PD-L1 expression, an integrated diagnostic approach is crucial for guiding personalized therapy and enhancing patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.